Recent Licenses and News Releases
Cincinnati Children's and Procter & Gamble Pharmaceuticals announce a new exclusive license agreement that gives P&GP rights to a novel heart failure target.
Girindus AG, a multinational company based in Germany, has licensed the patent rights to deoxyarbutin, a skin lightening compound owned by Cincinnati Children's through a patent donation by the Procter & Gamble Company.
The Ohio Third Frontier program announced a $500,000 grant to Cincinnati Children's. The grant will partially fund an internal seed investment fund known as the TOMORROW Fund, which will make investments in companies built around technologies developed at Cincinnati Children's.
Children's has licensed to e-Prime, LLC, a Cincinnati-based medical device development firm, the rights to a "spine staple" technology that may be used to treat scoliosis patients. e-Prime will create a new start-up company around the technology.
Cincinnati Children's has licensed software to itCube.
In September 2003, Cincinnati Children's and the Skin Sciences Institute received a patent donation relating to cubosome technology from The Procter & Gamble Company.
The goal of the Office of Intellectual Property & Venture Development is to commercialize inventions developed within Cincinnati Children's. The creation of an external advisory board -- comprised of venture capitalists, industry experts, and entrepreneurs -- will help to promote this goal.
Recently, Cincinnati Children's entered into a commercialization agreement with BTG.
